The MYO7A Gene Deafness Autosomal Recessive Type 2 Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the MYO7A gene that are linked to a form of hereditary hearing loss. This condition, known as autosomal recessive nonsyndromic deafness type 2 (DFNB2), is characterized by a significant reduction in hearing that is not associated with other symptoms or syndromes. The MYO7A gene plays a crucial role in the development and maintenance of hair cells within the inner ear, which are essential for normal hearing.
This genetic test involves the collection of a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory to detect any mutations in the MYO7A gene. It is particularly valuable for families with a history of hearing loss, providing insights into the genetic basis of the condition and informing decisions about further management or intervention.
The cost of the MYO7A Gene Deafness Autosomal Recessive Type 2 Genetic Test at DNA Labs UAE is set at 4400 AED. This investment covers the comprehensive analysis required to accurately identify mutations in the MYO7A gene, offering a crucial resource for affected individuals and their families seeking to understand the genetic underpinnings of their hearing loss.
The OTOA Gene Deafness Autosomal Recessive Type 22 Genetic Test is a specialized diagnostic procedure available at DNA Labs UAE, designed to detect mutations in the OTOA gene, which are associated with autosomal recessive deafness type 22 (DFNB22). This condition is characterized by non-syndromic sensorineural hearing loss, meaning it affects the inner ear or nerve pathways to the brain without other associated medical issues. The test is crucial for early diagnosis and management of the condition, particularly in families with a history of hearing loss. By analyzing a person's DNA, the test can confirm the presence of specific genetic alterations in the OTOA gene that lead to this form of deafness. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify these genetic markers. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test is a vital tool for individuals seeking to understand their genetic health, especially in the context of family planning or early intervention strategies for affected individuals.
The PCDH15 gene plays a crucial role in the development and maintenance of hair cells in the inner ear, which are essential for hearing. Mutations in the PCDH15 gene can lead to deafness autosomal recessive type 23 (DFNB23), a form of genetic hearing loss. This condition is characterized by the absence or severe reduction of hearing from birth.
To diagnose this specific type of genetic deafness, a genetic test targeting the PCDH15 gene can be conducted. DNA Labs UAE offers this specialized test, providing a comprehensive analysis to detect mutations in the PCDH15 gene that are responsible for DFNB23. The test is priced at 4400 AED and is designed to offer crucial information for affected individuals and their families, facilitating informed decisions regarding management and potential treatment options. This genetic test is a vital tool in the early diagnosis and understanding of DFNB23, contributing to the broader efforts in addressing genetic hearing loss.
The DIAPH1 gene, associated with Deafness Autosomal Dominant Type 1, plays a critical role in auditory function. Mutations in this gene can lead to a form of non-syndromic hearing loss, where the impairment of hearing is the only symptom presented, without affecting other systems of the body. The condition is inherited in an autosomal dominant pattern, meaning only one copy of the altered gene in each cell is sufficient to cause the disorder.
To identify mutations in the DIAPH1 gene, a specific genetic test is available at DNA Labs UAE. This test is a crucial tool for diagnosing individuals with hearing loss that may be attributed to this genetic variant. It involves analyzing the DNA to detect mutations in the DIAPH1 gene that are known to cause autosomal dominant deafness.
The cost of the DIAPH1 Gene Deafness Autosomal Dominant Type 1 Genetic Test at DNA Labs UAE is 4400 AED. This test is not only vital for the accurate diagnosis of the condition but also plays a significant role in family planning and genetic counseling for families affected by this type of hearing loss. By identifying carriers of the gene mutation, families can make informed decisions about future pregnancies, and individuals can receive tailored advice and support for managing their condition.
The EYA4 gene plays a critical role in the development of the auditory system, and mutations in this gene can lead to hearing loss. Autosomal Dominant Deafness Type 10, linked to the EYA4 gene, is a genetic condition characterized by progressive, sensorineural hearing loss. Individuals with this condition typically begin to experience hearing impairment in childhood or early adulthood, which can vary in severity.
To diagnose this specific type of hearing loss, a genetic test targeting the EYA4 gene can be conducted. This test is crucial for individuals with a family history of hearing loss or for those experiencing symptoms of hearing impairment without a clear cause. It involves analyzing the DNA to identify mutations in the EYA4 gene that are known to be associated with Autosomal Dominant Deafness Type 10.
In the UAE, DNA Labs offers this specialized genetic test. The cost of the test is 4400 AED, a price that reflects the comprehensive analysis and the specific expertise required to interpret the results accurately. Conducting the test at DNA Labs UAE ensures that individuals receive precise information about their genetic status concerning the EYA4 gene, facilitating informed decisions about management and treatment options for hearing loss. This test is an invaluable tool for affected families, providing them with the necessary insights to understand their condition better and potentially prevent further hearing deterioration through early intervention.
The MYO7A Gene Deafness Autosomal Dominant Type 11 Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE, aimed at identifying mutations in the MYO7A gene, which are linked to a form of autosomal dominant non-syndromic hearing loss. This condition, known as Autosomal Dominant Deafness Type 11, is characterized by varying degrees of hearing impairment that can affect individuals differently, even within the same family. The test is crucial for families with a history of hearing loss, as it can provide valuable insights into the genetic underpinnings of their condition, enabling informed decisions about management and treatment options. Conducted in a state-of-the-art laboratory setting, the test involves analyzing the patient's DNA sample to look for specific genetic alterations associated with this type of hearing loss. The cost of the MYO7A Gene Deafness Autosomal Dominant Type 11 Genetic Test at DNA Labs UAE is 4400 AED, reflecting the advanced technology and expertise required to accurately identify the presence of MYO7A gene mutations.
The TECTA Gene Deafness Autosomal Dominant Type 12 Genetic Test is a specialized diagnostic tool used to identify mutations in the TECTA gene, which can lead to autosomal dominant non-syndromic hearing loss, specifically categorized as type 12. This form of hearing loss is characterized by its genetic inheritance pattern, where a single copy of the altered gene in each cell is sufficient to cause the condition. The TECTA gene is crucial for the proper development and function of the inner ear, which plays a significant role in the ability to hear.
Conducted at DNA Labs UAE, this genetic test is designed to provide individuals and families with crucial information regarding the genetic basis of their hearing loss, facilitating early diagnosis and intervention strategies. With a cost of 4400 AED, the test is a valuable resource for those with a family history of hearing loss or for individuals experiencing hearing difficulties, aiming to understand the genetic underpinnings of their condition. By identifying specific mutations in the TECTA gene, healthcare providers can offer more personalized management plans and genetic counseling, helping affected individuals and their families navigate the challenges associated with hearing loss.
The COL11A2 gene plays a crucial role in the production of a specific type of collagen, which is essential for the proper development and maintenance of structures within the ear. Mutations in the COL11A2 gene are associated with autosomal dominant non-syndromic hearing loss, specifically categorized as Deafness, Autosomal Dominant Type 13 (DFNA13). This condition is characterized by the progressive loss of hearing, which typically begins in childhood or early adulthood.
To diagnose this specific genetic cause of hearing loss, DNA Labs UAE offers a genetic test that targets the COL11A2 gene. This test is designed to identify mutations within the gene that are known to result in DFNA13. It is a crucial tool for families with a history of hearing loss, as it can provide a definitive diagnosis, guide treatment decisions, and inform family planning.
The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or a cheek swab. The sample is then analyzed in the laboratory for the presence of mutations in the COL11A2 gene. Results from the test can help in understanding the genetic basis of hearing loss in affected individuals and facilitate genetic counseling for the family. It is important for potential patients to consult with a healthcare provider or a genetic counselor before and after undergoing genetic testing to fully understand the implications of the test results.
The POU4F3 gene is associated with Autosomal Dominant Deafness Type 15 (DFNA15), a genetic condition that affects hearing. The POU4F3 gene plays a crucial role in the development and maintenance of hair cells in the inner ear, which are essential for normal hearing. Mutations in the POU4F3 gene can lead to progressive hearing loss, typically starting in late childhood or early adulthood.
To diagnose this specific type of genetic deafness, DNA Labs UAE offers a genetic test targeting the POU4F3 gene. This test is designed to identify mutations in the POU4F3 gene that are responsible for Autosomal Dominant Deafness Type 15. Early identification of these mutations can be beneficial for affected individuals and their families for several reasons, including understanding the cause of the hearing loss, exploring potential treatment options, and making informed decisions about family planning.
The cost of the POU4F3 Gene Deafness Autosomal Dominant Type 15 Genetic Test at DNA Labs UAE is 4400 AED. This investment includes the collection of a DNA sample, usually through a blood draw or cheek swab, and comprehensive analysis to detect any mutations in the POU4F3 gene. Results from this test can provide valuable information for managing and treating hearing loss associated with DFNA15.
The MYH9 Gene Deafness Autosomal Dominant Type 17 Genetic Test is a specialized diagnostic tool designed to identify mutations in the MYH9 gene, which are linked to a specific form of hearing loss known as Autosomal Dominant Nonsyndromic Deafness Type 17 (DFNA17). This condition is characterized by its inheritance pattern, where only one copy of the mutated gene, inherited from an affected parent, is sufficient to cause the disorder. The MYH9 gene plays a crucial role in the development and function of the inner ear structures, which are essential for normal hearing.
Conducted at DNA Labs UAE, this genetic test involves analyzing the patient's DNA, extracted from a blood sample, to search for mutations in the MYH9 gene. The process is highly sophisticated and requires advanced laboratory techniques to accurately identify the genetic alteration responsible for the hearing impairment.
The cost of the MYH9 Gene Deafness Autosomal Dominant Type 17 Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the intricate nature of the testing process and the specialized expertise required to interpret the results. Patients undergoing this test can expect a comprehensive analysis that will not only aid in confirming a diagnosis of DFNA17 but also provide essential information for family planning and management of the condition. The test is a critical step for affected families in understanding their genetic makeup and assessing the risk of passing the condition on to future generations.
